Operated by the British Business Bank, the Investment Fund for Northern Ireland provides equity and debt funding to smaller businesses across the region.
Portfolio
5
companies
Cirdan
Cirdan provides software and imaging solutions to accelerate and improve disease diagnosis.
Cumulus Neuroscience
Digital biomarker platform provider for neuroscience clinical trials and patient monitoring.
Neurovalens
Neurovalens creates wearable devices that stimulate the brain to address metabolic and health issues.
Reform RX
Reform RX produces digitally connected Pilates equipment equipped with biometric tracking technology.
The Present Tree
The Present Tree provides luxury tree gifting experiences with a focus on sustainability.
Neil Simms
Investment Director
Mark Sterritt
Director of Nations and Regions Investment Funds
The County Antrim-based luxury gifting brand has secured its first equity funding round to scale operations and expand into new markets.
"Growing The Present Tree from an ambitious idea to the thriving business we see today has been an incredible journey. I am so proud of our team who have shown such devotion to the business and always ensure every tree gift we send carries the spark of love and meaning that is at the heart of The Present Tree."
The investment round was led by the Investment Fund for Northern Ireland to support international commercial expansion and product development.
"We’re delighted to have the support of the Investment Fund for Northern Ireland and our other new and existing investors at this key stage in our journey. This funding will enable us to significantly scale sales of our current medical devices, and also to extend our product portfolio through additional FDA approvals. Our technology offers an entirely new approach to treating serious global health challenges through safe, non-invasive neurostimulation."
The investment was led by Whiterock with participation from regional funds and angel backers.
"There is a substantial unmet need today in neuroscience clinical studies. Many study endpoints are measured with traditional pen and paper assessments which lack objective data about brain function. Biopharma companies need objective data to effectively establish baseline information about whether a drug is engaging with the region of the brain that a particular drug is targeting, whether a drug is effective, and informing which cohort of patients may benefit the most from a particular drug."
The £7.5m financing comprises backing from 57 Stars and the Investment Fund for Northern Ireland.
"The backing of 57 Stars and the Investment Fund for Northern Ireland is a testament to the value and potential of our technology."
Clarendon Fund Managers led the £3.8m financing round to support international growth and product development.
"With Neal and Yvette at the helm, Reform RX is an ambitious company that shares our vision for the future. It will be the must-have piece of equipment for every Reformer Pilates enthusiast and studio. The deal is the largest initial investment we have ever completed in a single NI company here at Clarendon, which is a reflection of the confidence we have in the team at Reform RX. I can’t wait to see how their journey develops from here."
